Couple of broker upgrades - from ********* Credit Suisse Revenue...

Couple of broker upgrades - from *********
Credit Suisse
Revenue was ahead of Credit Suisse's forecasts in the fourth quarter. Higher revenue growth is forecast across all segments through FY17, based on a robust industry performance and the company's ability to retain a dominant position.
Target rises to $9.80 from $9.15 on the back of the model roll over and updated currency forecasts. Outperform rating retained.
Sector: Health Care Equipment & Services.
Target price is $9.80.Current Price is $9.20. Difference: $0.60 - (brackets indicate current price is over target). If RMD meets the Credit Suisse target it will return approximately 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).

UBS
Despite a difficult comparable period UBS observes sales in the fourth quarter were ahead of expectations. The company has confirmed it expects a new mask launch within 2016.
UBS  flags upside potential for ResMed, with the mask opportunity an inflection point for gross margin. Modest upside is factored into 2017 forecasts. Buy rating retained. Target rises to US$77.60 from US$73.50.
Sector: Health Care Equipment & Services.
Current Price is $9.22. Target price not assessed.